Current Problems in Cancer
Volume 33, Issue 5 , Pages 302-326 , September 2009

Anal Cancer: Progress on Combined-Modality and Organ Preservation

  • Emily Chan, MD, PhD

      Affiliations

    • Assistant Professor, Division of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Lisa A. Kachnic, MD

      Affiliations

    • Professor and Chair, Department of Radiation Oncology, Boston University School of Medicine, Boston, Massachusetts
    • ,
  • Charles R. Thomas Jr, MD

      Affiliations

    • Professor and Chair, Department of Radiation Medicine, Professor, Division of Hematology/Oncology, Department of Medicine, OHSU Knight Cancer Institute, Portland, Oregon

References 

  1. American Cancer Society. Cancer Facts and Figures 2009, vol 4. Atlanta, GA: American Cancer Society; 2009;
  2. Ryan DP, Comptom CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000;342:792–800
  3. Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987;317:973–977
  4. Holly EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ, Kristiansen JJ. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst. 1989;81:1726–1731
  5. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337:1350–1358
  6. Penn I. Cancers of the anogenital region in renal transplant recipients (Analysis of 65 cases). Cancer. 1986;58:611–616
  7. Arends MJ, Benton EC, McLaren KM, Stark LA, Hunter JA, Bird CC. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer. 1997;75:722–728
  8. Palefsky JM, Holly EA, Gonzales J, Berline J, Ahn DK, Greenspan JS. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res. 1991;51:1014–1019
  9. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus non-infected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52:203–208
  10. Oehler-Jänne C, Huguet F, Provencher S, Seifert B, Negretti L, Riener MO, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26:2550–2557
  11. Gunderson LL, Moughan J, Ajani JA, et al. Anal carcinoma: Impact of TN category of disease on survival and disease relapse in the US GI InterGroup RTOG 98-11 phase III trial. Proceedings of the GI Cancer Symposium, Orlando, FL. 2010;
  12. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A. Outcomes and prognostic factors for squamous cell carcinoma of the anal canal: analysis of patients from the National Cancer Database. Dis Colon Rectum. 2009;52:624–631
  13. Ajani JA, Winter KA, Gunderson LL, et al. Intergroup RTOG 98-11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006;24(18S):4009
  14. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, et al. Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys. 2009;75:428–435
  15. Beck DE, Karulf RE. Combination therapy for epidermoid carcinoma of the anal canal. Dis Colon Rectum. 1993;37:1118–1125
  16. Salmon RJ, Fenton J, Asselain B, Mathieu G, Girodet J, Durand JC, et al. Treatment of epidermoid anal canal cancer. Am J Surg. 1984;147:43–48
  17. Papillon J, Mayer M, Montbarbon JF, Gerard JP, Chassard JL, Bailly C. A new approach to the management of epidermoid carcinoma of the anal canal. Cancer. 1983;51:1830–1837
  18. Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal cancer: a preliminary report. Dis Colon Rectum. 1974;17:354–356
  19. Buroker TR, Nigro N, Bradley G, Pelok L, Chomchai C, Considine B, et al. Combined therapy for cancer of the anal canal: a follow up report. Dis Colon Rectum. 1977;20:677–678
  20. Nigro ND, Vaitkevicius VK, Buroker T, Bradley GT, Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum. 1981;24:73–75
  21. Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51:1826–1829
  22. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348:1049–1054
  23. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–2049
  24. Flam M, John M, Pajak TF, Patrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–2539
  25. Hung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, et al. Cisplatin-based combined modality therapy for anal carcinoma. Cancer. 2003;97:1195–1202
  26. Ajani HA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. J Am Med Assoc. 2008;299:1914–1921
  27. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, et al. US Intergroup Anal Carcinoma Trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009;27:1116–1121
  28. James R, Wan S, Glynne-Jones R, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5-FU in squamous cell carcinoma of the anus (ACT II) (2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition)). J Clin Oncol. 2009;27(18S):LBA4009
  29. Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25:4581–4586
  30. Kachnic L, Winter R, Myerson R, et al. RTOC 0529: a phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal (Proceedings of the 51st Annual ASTRO Meeting, Chicago, IL). J Radiat Oncol Biol. 2009;75:S1–S5
  31. Doniec JM, Schniewind B, Kovács G, Kahlke V, Loehnert M, Kremer B. Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. Surg Endosc. 2006;20:673–678
  32. Hwang JM, Rao AR, Cosmatos HA, Wang R, Kaptein JS, Kagan RA, et al. Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial 192Ir implantation: a 10 year experience. Brachytherapy. 2004;3:95–100
  33. Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Glanzmann C, Ciernik IF. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy. 2007;6:218–226
  34. Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?. J Acquir Immune Defic Syndr. 2004;37:1563–1565
  35. Cru-Cianflone N, Hullsiek KH, Weintrob A, et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. Cape Town, South Africa: Fifth International AIDS Society. Conference on HIV Pathogenesis, Treatment and Prevention; 2009;
  36. Kim JH, Sarani B, Orkin BA, Young HA, White J, Tannebaum I, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum. 2001;44:1496–1502
  37. Holland JM, Swift PS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology. 1994;193:251–254
  38. Peddada AV, Smith DE, Rao AR, Frost DB, Kagan AR. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 1997;37:1101–1105
  39. Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44:127–131
  40. Edelman S, Johnstone PAS. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2006;66:206–211
  41. Wexler A, Berson AM, Goldstone SE, Waltzman R, Penzer J, Maisonet OG, et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2008;51:73–81
  42. Hogg ME, Popowich DA, Wang EC, Kiel KD, Stryker SJ, Halverson AL. HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum. 2009;52:891–897
  43. Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol. 2008;26:474–479
  44. Renhan AG, Saunders MP, Schofield PF, O'Dwyer ST. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg. 2005;92:605–614
  45. Akbari RP, Paty PB, Guillem JG, Weiser MR, Temple LK, Minsky BD, et al. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum. 2004;47:1136–1144
  46. Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14:2780–2789
  47. Jhawer M, Mani S, Lefkopoulou M, Hahn RG, Harris J, Catalano PJ, et al. Phase II study of mitomycin-C, Adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an Eastern Cooperative Oncology Group study E7272. Investig New Drugs. 2006;24:447–454
  48. Phan LK, Hoff PM. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum. 2007;50:395–398
  49. Schellens JHM. Capecitabine. Oncologist. 2007;12:152–155

PII: S0147-0272(09)00048-8

doi: 10.1016/j.currproblcancer.2009.10.003

Current Problems in Cancer
Volume 33, Issue 5 , Pages 302-326 , September 2009

Article Tools